Vitamin B2 Pathway Identified as Potential Target for Cancer Therapy

Why It Matters

Targeting the riboflavin‑FSP1 axis could weaken cancer cells' redox defenses, opening a new avenue for ferroptosis‑based therapies. The finding also extends to neurodegeneration and transplant injury where ferroptosis plays a role.

Key Takeaways

• Riboflavin stabilizes ferroptosis suppressor protein FSP1.
• Vitamin B2 deficiency sensitizes cancer cells to ferroptosis.
• Roseoflavin induces ferroptosis at low concentrations.
• Inhibiting riboflavin pathway may enhance cancer therapy.
• Ferroptosis modulation impacts neurodegeneration and transplantation injury.

Pulse Analysis

Ferroptosis, a form of programmed cell death driven by iron‑catalyzed lipid peroxidation, has emerged as a critical vulnerability in many cancers. Recent work from the Rudolf Virchow Centre used a genome‑wide CRISPR‑Cas9 screen to pinpoint riboflavin metabolism as a key regulator of this pathway. By maintaining the stability of ferroptosis suppressor protein 1 (FSP1), vitamin B2 enables tumor cells to recycle lipid‑soluble antioxidants and avoid lethal phospholipid damage. This mechanistic insight links a common dietary nutrient to the redox defenses that cancers exploit.

The therapeutic implications are immediate. The team showed that roseoflavin, a natural riboflavin mimic produced by bacteria, can disrupt the vitamin‑B2‑FSP1 axis and provoke ferroptosis in cancer cell lines at nanomolar concentrations. While a dedicated small‑molecule inhibitor of riboflavin metabolism remains elusive, the proof‑of‑concept data suggest that pharmacologically lowering intracellular riboflavin or blocking its cofactors could sensitize tumors to existing ferroptosis inducers. Drug developers may therefore consider combination regimens that pair riboflavin pathway blockers with iron‑or lipid‑targeting agents to achieve synergistic tumor kill.

Beyond oncology, the study broadens the relevance of riboflavin‑driven ferroptosis control to neurodegenerative disorders, organ transplantation, and ischemia‑reperfusion injury, where excessive or insufficient ferroptosis contributes to pathology. Understanding how dietary vitamins intersect with cell‑death pathways could inform precision nutrition strategies and novel adjunct therapies across multiple disease arenas. As pre‑clinical models advance, investors and biotech firms are likely to monitor this space closely, anticipating a new class of metabolism‑focused therapeutics that leverage ferroptosis for clinical benefit.